Using routine blood tests to predict severe immune-related adverse events during immune checkpoint inhibitor treatment
A high baseline eosinophil count and a lower RDW early on during therapy identify patients at increased risk of severe irAEs. These accessible measures could support personalised monitoring and biomarker-guided patient selection. However, external validation is needed to confirm the robustness and validate the thresholds identified in this study prior to clinical use.
Authors
- Haydar Çağatay Yüksel (ORCID: https://orcid.org/0000-0001-8857-2983)
- Burçak Karaca (ORCID: https://orcid.org/0000-0003-2638-1625)
- Erdem Göker (ORCID: https://orcid.org/0000-0001-6180-713X)
- Caner Acar (ORCID: https://orcid.org/0000-0002-9782-6807)
- Fatma Pınar Açar (ORCID: https://orcid.org/0009-0000-2749-8732)
- Gökhan Şahin (ORCID: https://orcid.org/0000-0003-1478-9383)
Institutions
- Ege University (TR)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-12-13
- DOI
- https://doi.org/10.1186/s12885-025-15460-7
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05